The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) has selected four projects to fund and oversee, all focused on the use of enzalutamide in treating prostate cancer. Grant funding will be provided by Pfizer Global Medical Grants and Astellas Pharma Global Development.
“This research will help us advance scientific knowledge on the mechanisms of resistance, underlying biology, and clinical effectiveness of enzalutamide-based therapy in prostate cancer,” said Crystal S. Denlinger, MD, FACP, Senior Vice President, Chief Scientific Officer, NCCN. “Congratulations to all of the grantees. We look forward to findings that may guide the development of enzalutamide and its combination with other therapies.”
The selected projects are:
Proposals were peer reviewed by a Scientific Review Committee, which consisted of leading expert oncologists from NCCN Member Institutions. The selected priority areas focused on the development of novel treatment approaches because of their ability to impact the unmet needs for patients with potentially lethal prostate cancer. The projects are set to be completed within three years. Collectively, the total amount of grants awarded for this study are approximately $2 million.Back To Top
Prostate Cancer Research Projects Get Funding. Appl Rad Oncol.